News

Pulmonary fibrosis patients are at high-risk of complications related to COVID-19 and need protections that reduce their chance for exposure to the virus. At the same time, many pulmonary fibrosis patients rely on pulmonary rehabilitation (PR) services. PR has been shown to improve many PF patients’ exercise capacity and health-related quality of life. Because there are limited treatment options for PF, pulmonary rehabilitation is all the more essential for helping to maintain PF patients’ health.

CMS guidelines for supplemental oxygen adjusted to protect patients during COVID-19 crisis

To limit or prevent the spread of COVID-19, several recommendations have been suggested by the Centers for Disease Control (CDC). Read our FAQ for pulmonary fibrosis patients.

The Pulmonary Fibrosis Foundation medical team is actively monitoring the evolving outbreak of the COVID-19 coronavirus to evaluate the potential health implications for the pulmonary fibrosis (PF) community in the USA. Read our Guidance Statement here.

The Pulmonary Fibrosis Foundation medical team is actively monitoring the evolving outbreak of the COVID-19 coronavirus to evaluate the potential health implications for the pulmonary fibrosis (PF) community in the USA.

The Pulmonary Fibrosis Foundation and Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company, have created a consortium called PROLIFIC (Prognostic Lung Fibrosis Consortium) to develop well-qualified assays to detect important peripheral blood protein biomarkers in patients with pulmonary fibrosis. The assays will be used to uncover early indicators of a drug’s activity.